NasdaqHealth CareBiological Products, (No Diagnostic Substances)ISELIN, NJ

Outlook Therapeutics, Inc. OTLK

Ask your AI

Estimated market cap $100.54M243.45M shares, shares as of Aug 14, 2026CIK 1649989

Insider trades, 12 mo

10 buys · 0 sells

$7.91M bought, open market

Congress trades, 24 mo

—

No disclosed trades

13F holders, Q3 2026

11.9% of shares · 17 added

13F holders

…

Lobbying, 12 mo

—

No lobbying filings

Federal contracts, 12 mo

—

None matched

Ask your AI:

Latest 10-Q

Q2 2026

What changed in Outlook Therapeutics, Inc.'s latest quarterly report, compared with the one before.

Filed Aug 18, 2026 · Quarter ended Jun 30, 2026

Compared with the 10-Q for the quarter ended Mar 31, 2026. Sections compared: risk factors and legal proceedings.

Read the 10-Q on sec.gov ↗Filing index ↗

Latest 10-Q

What changed in Outlook Therapeutics, Inc.'s latest quarterly report, compared with the one before.

Loading…

Insider trades

10 in 12 mo

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

No open-market insider trades reported since Aug 14, 2026. Insiders have two business days to file.

Recent insider trades

Lawrence A. Kenyon Chief Financial Officer, Director	Aug 14 Form 4 ↗	Buy	— 101,010 sh	-42.6%
Robert Charles Jahr Chief Executive Officer, Director	Aug 14 Form 4 ↗	Buy	— 151,515 sh	-42.6%
Ghiath M. Sukhtian Director, 10% owner	Aug 12 Form 4 ↗	Buy	+$2.5M 2.53M sh @ $0.99	-60.1%
Faisal Ghiath Sukhtian Director	Jul 29 Form 4 ↗	Buy	+$100.2K 95,398 sh @ $1.05	-62.1%
Yezan Munther Haddadin Director	Jun 2 Form 4 ↗	Buy	+$24.1K 29,000 sh @ $0.83	-48.6%

All OTLK insider trades →Planned sales (Form 144): see notices

Insider trades

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

Loading…

13F holders

28.85M shares

54 funds report OTLK. Values checked against market prices.

Funds own 8.4% of shares (Q2 2026)

70 funds hold the stock.

Q3 2026: 12% · 5,560 of ~8,900 funds reported so far

Q2 202514%
Q3 20259.2%
Q4 202511%
Q1 20268.9%
Q2 20268.4%
Q3 2026 (so far)12%

Q3 2026. 15 new, 17 added to, 9 trimmed, 29 exited since Q2 2026.

Top 13F holders
#
1	Vanguard Capital Management LLC 13F ↗	8.98M	$5.2M	+105.1%
2	Marshall Wace, LLP 13F ↗	8.02M	$4.6M	+303.7%
3	UBS Group AG 13F ↗	3.34M	$1.9M	+2096.4%
4	Geode Capital Management, LLC 13F ↗	1.72M	$984.7K	+37.8%
5	BlackRock, Inc. 13F ↗	1.67M	$956.5K	unchanged
6	Renaissance Technologies LLC 13F ↗	1.12M	$642.7K	New
7	Vanguard Fiduciary Trust Co 13F ↗	1.07M	$613.0K	+61.4%
8	State Street Corp 13F ↗	569,702	$326.7K	+5.5%
9	Hudson Bay Capital Management LP 13F ↗	383,687	$220.0K	New
10	Raymond James Financial Inc 13F ↗	332,051	$190.4K	unchanged

Download CSV Every fund that holds OTLK, not only these ten. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

13F holders

Funds that report this stock, checked against market prices.

Loading…

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

No recent congressional trades for this company.

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

Loading…

Lobbying

What Outlook Therapeutics, Inc. and its lobbying firms report each quarter.

No recent lobbying filings for this company.

Lobbying

What Outlook Therapeutics, Inc. and its lobbying firms report each quarter.

Loading…

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Funds holding the stock

Shares they report, adjusted for splits

Funds holding the stock by quarter

Q1 2023	1	—	1,710	$37.3K
Q2 2023	1	0	1,710	$59.5K
Q3 2023	1	0	1,710	$7,557
Q1 2024	53	+52	7.26M	$86.5M
Q2 2024	63	+10	8.05M	$59.4M
Q3 2024	65	+2	7.94M	$42.4M
Q4 2024	61	-4	4.55M	$8.6M
Q1 2025	64	+3	7.09M	$8.6M
Q2 2025	67	+3	6.00M	$9.6M
Q3 2025	55	-12	4.08M	$4.3M
Q4 2025	54	-1	6.82M	$10.8M
Q1 2026	55	+1	10.73M	$2.2M
Q2 2026	70	+15	20.45M	$32.5M
Q3 2026	54	-16	28.85M	$16.5M

Each point is a quarter-end, from Q1 2023 to Q3 2026. A fund's 13F lists its long positions in US-listed securities as of the last day of the quarter and arrives up to 45 days later, so each point shows holdings at quarter-end, not on the day they were reported.

Common shares only; options and bonds are left out. When a fund amends a report, the amended version is the one counted.

The history follows the company's current CUSIP number (69012T305). If the company's shares were ever re-issued under a different CUSIP, the quarters before the change are not part of this series, so the first point (Q1 2023) can be later than the stock's first appearance in 13F reports.

Share counts are adjusted for stock splits (1-for-20 on Mar 14, 2024): reports from before a split are multiplied by its ratio, so every quarter is on the share count of Q3 2026.

A quarter appears once our daily update has built its summary. If a summary cannot be built, older reports are kept and the chart shows the quarters it has until the next update repairs it.

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Loading…

More filings and data

Each opens the table.

Ownership stakes6 in 12 mo 8-K events3 in 90 days PatentsNone on record Short interestFINRA · updated Oct 15 Planned insider salesNone in 12 mo Executive payNone on record Wikipedia attentionNone on record SEC enforcementNone on record Clinical trials1 active FDA decisionsLatest Jul 24 IPO history6 registrations Ownership stakes…8-K events…Patents…Short interest…Planned insider sales…Executive pay…Wikipedia attention…SEC enforcement…

About the company

The basics from the company’s SEC registration.

Legal name: Outlook Therapeutics, Inc.
Address: 111 S. WOOD AVENUE, UNIT #100, ISELIN, NJ 08830
Phone: 6096193990
Fiscal year ends: Sep 30
Filer category: Non-accelerated filer, smaller reporting company
Incorporated in: DE
Listed as: OTLK (Nasdaq)
Former names: Oncobiologics, Inc. (until 2018)
SEC filings: All filings on SEC EDGAR ↗

About the company

The basics from the company’s SEC registration.

Loading…

$0.413−$0.03 (−6.16%) Nov 13 close

1M3M1Y

Oct 13, 2026Low $0.413 · High $0.5638Nov 13, 2026

Aug 13, 2026Low $0.413 · High $0.8888Nov 13, 2026

Nov 13, 2025Low $0.1981 · High $2.47Nov 13, 2026

Congress purchase Congress sale Insider sale over $1M

Adjusted for stock splits; not for dividends. Where prices come from.

Live chart

Intraday and historical prices from TradingView. Quotes may be delayed.

Loading chart…

Information, not investment advice. Company matching is automatic; check the source before relying on one row.